<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Commonly used drugs for the treatment of colon{} <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients like <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 shows severe side effects or induces resistance in clinical settings </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, we analyzed a combination of PLK1 (polo-like kinase 1)-specific <z:mp ids='MP_0000417'>short hair</z:mp> <z:chebi fb="40" ids="33697">RNA</z:chebi> (shRNA), a potent tool to destroy mitosis in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, together with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 to enhance drug sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>Cellular proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were determined in SW620 colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Knockdown of cellular PLK1 led to the decreased <z:chebi fb="2" ids="33699">mRNA</z:chebi> and PLK1 protein in RT-PCR and western blot assay </plain></SENT>
<SENT sid="4" pm="."><plain>The viability declined (p&lt;0.001) in <z:chebi fb="0" ids="53233">MTT</z:chebi> assay and colony formation assay, and the number of apoptotic cells was clearly increased (p&lt;0.01) in flow cytometric analysis and Hoechst 33258 staining compared with control cells after incubation with PLK1-specific shRNA and SN-38 </plain></SENT>
<SENT sid="5" pm="."><plain>We found the level of cleaved PARP was also increased in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo, employment of shRNA targeting PLK1 improved the sensitivity to treat SW620 <z:mp ids='MP_0003815'>nude</z:mp> mouse model toward <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 </plain></SENT>
<SENT sid="7" pm="."><plain>The combination therapy inhibited cellular proliferation and promoted <z:mpath ids='MPATH_3'>apoptosis</z:mpath> observed at the percentage of PCNA and caspase3 by immunohistochemistry, accompanied with TUNEL assay </plain></SENT>
<SENT sid="8" pm="."><plain>As we expect, the combination treatment delayed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> (p&lt;0.01) and simultaneously reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> weight (p&lt;0.01) compared with control group </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, combination of PLK1-specific shRNA interference with low-dose <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 triggered a antitumor efficacy and represented a potential strategy to treat <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>